Dihydroberberine normalizes insulin secretion by regulating glucokinase
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Chenyang Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medi…. Hauptthemen laut MEDLINE: Glucokinase, Insulin Secretion, Berberine, Insulin-Secreting Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, Cultivation Fund of Capital Medical University.
Abstract (Originalsprache)
Aim
Berberine (BBR) is a well‐established natural product lowing glucose and promoting insulin secretion in mice and diabetic patients. However, the bioavailability of BBR is low and the target remains unclear. Here, a BBR analog dihydroberberine (DHB) showed higher bioavailability in promoting insulin secretion by targeting glucokinase (GCK) that has been reported as a powerful regulator of diabetes by promoting insulin secretion. Materials and Methods To evaluate the effects and mechanisms of drugs in MIN6 and INS‐1 cells, cell viability, glucose‐stimulated insulin secretion (GSIS) and the expression of genes associated with insulin secretion and cell function were assessed. Glucose tolerance, insulin secretion and insulin tolerance experiment were conducted to confirm the effects of DHB in vivo. Molecular docking, CETSAs, and knockdown experiments were used to predict and validate the target.
Results
DHB promoted glucose‐stimulated insulin secretion (GSIS) in INS‐1 and MIN6 cells. DHB might be one of the most effective BBR analog, as validated by the improved oral glucose tolerance test (GTT) and insulin released test (IRT) assays in mice. In addition, molecular docking and cellular thermal shift assay (CETSA) revealed that DHB formed compact complexes with GCK. Importantly, the effects of DHB were significantly diminished in INS‐1 cells upon deprivation of GCK in siRNA knockdown assay, supporting that GCK is required for DHB promoting glucose‐stimulated insulin secretion (GSIS) and preventing cell apoptosis in pancreatic β‐cells.
Conclusions
Our findings suggest DHB might be one of the most effective compound via regulating GCK.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Traditional Chinese Medicine (TCM) Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Department of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Center for Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Cultivation Fund of Capital Medical University
- Beijing Tongren Hospital Seed Funds
Zitieren
APA
Zhang, C., Zhang, X., Zhang, Q., Zhao, R., Xiong, F., Wei, G., Ke, X., & Lu, J. (2026). Dihydroberberine normalizes insulin secretion by regulating glucokinase. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70171
Vancouver
Zhang C, Zhang X, Zhang Q, Zhao R, Xiong F, Wei G, et al. Dihydroberberine normalizes insulin secretion by regulating glucokinase. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70171
BibTeX
@article{Zhang2026,
author = {Zhang, Chenyang and Zhang, Xuelian and Zhang, Qianrui and Zhao, Ruxuan and Xiong, Fengran and Wei, Gang and Ke, Xisong and Lu, Jing},
title = {Dihydroberberine normalizes insulin secretion by regulating glucokinase},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70171}
}
EUVIMED